Global Angiomyolipoma Market, By Treatment Type (Medicines, Surgery), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Angiomyolipoma Market Analysis and Size
The global angiomyolipoma market is expected to witness significant growth during the forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. The growth of angiomyolipoma market enhanced by the growing cases of angiomyolipoma and rise in research and development activities conducted by many pharmaceuticals’ companies. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global angiomyolipoma market in the forecast period 2022-2029. The expected CAGR of global angiomyolipoma market is tend to be around 6.50% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Angiomyolipoma is the most common benign renal tumor composed of blood vessels, smooth muscle cells and fat cells. It is formed on the kidney and impair the function which eventually leads to the chronic kidney diseases and hypertension.
Angiomyolipoma Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Treatment Type (Medicines, Surgery), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Hikma Pharmaceuticals Inc (U.S.), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Alkem Labs (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), NATCO Pharma Limited (India)
|
|
Market Opportunities
|
|
Global Angiomyolipoma Market Dynamics
Drivers
- Increase in Geriatric Population
The geriatric population is expected to increase the patient population globally, which boots the global angiomyolipoma market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Rising Incidence of Angiomyolipomas
Angiomyolipomas (AMLs) are the most common benign renal tumour, with an incidence varying between 0.2% and 0.6% and a strong female domination. They occur as isolated entities in 80% of cases and thus is driving the market growth.
- Increasing Demand for Retail Pharmacies
The rise in the number of angiomyolipoma therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global angiomyolipoma market over a forecast period.
- High Cost
The huge expenditure associated with global angiomyolipoma medications surely hamper the market growth.
This global angiomyolipoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global angiomyolipoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Angiomyolipoma Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.
In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will leave a significant impact on the angiomyolipoma market.
Global Angiomyolipoma Market Scope
The global angiomyolipoma market is segmented on the basis of treatment type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Medicines
- Surgery
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Angiomyolipoma Market Regional Analysis/Insights
The global angiomyolipoma market is analysed and market size insights and trends are provided by treatment type, distribution channel and end-user as referenced above.
The major countries covered in the global angiomyolipoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for angiomyolipoma market throughout the forecasted period owing to the global leaders in research and development activities and rise in patient assistance programs.
Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Angiomyolipoma Market Share Analysis
The global angiomyolipoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global angiomyolipoma market
Key players operating in the global angiomyolipoma market include:
- Novartis AG (Switzerland)
- Hikma Pharmaceuticals PLC (U.S.)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Alkem Labs (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- NATCO Pharma Limited (India)
SKU-